• Molecular NameKetanserin
  • SynonymNA
  • Weight395.434
  • Drugbank_IDN/A
  • ACS_NO74050-98-9
  • Show 3D model
  • LogP (experiment)3.29
  • LogP (predicted, AB/LogP v2.0)3.56
  • pkaN/A
  • LogD (pH=7, predicted)3.17
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.74
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA69.72
  • StatusN/A
  • AdministrationN/A
  • PharmacologyA drug with affinity for multiple GPCR receptors.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding95.1
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe major metabolic pathway is by ketone reduction leading to formation of ketanserin-ol which is mainly excreted in the urine. Ketanserin-ol is partly reoxidised into ketanserin [2036747]. The major phase 1 metabolic pathways of ketanserin in mammals are: (a) aromatic hydroxylation at the quinazolinedione; (b) ketone reduction, (c) oxidative N-dealkylation at the piperidine nitrogen.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A